Study Links Psychedelics to Reduced Risk of Heart Disease

A recent study published in Scientific Reports suggests that individuals who have used traditional psychedelics may be at lower risk for cardiac disease. While these new findings are exciting, they serve to highlight the need for further research into the potential medical uses of psychedelics like psilocybin, LSD, and ketamine.

“In our previous research, we have found associations between lifetime classic psychedelic use and lower odds of being overweight or obese as well as lower odds of having hypertension in the past year, both of which are risk factors of cardiometabolic disease,” reports study author Ottos Simonsson Ph.D., of Oxford University.

In another article published in the Journal of Psychopharmacology earlier in the year, research posited “that psychedelic substances such as psilocybin could be used to assist in promoting positive lifestyle changes conducive to good health.” Simonsson notes that the use of traditional psychedelics has been linked to spontaneous, positive lifestyle and health changes such as reduced alcohol consumption, lowered or eliminated the use of tobacco products, and increased exercise.

Simonsson’s study also indicates that traditional psychedelics may improve mental health conditions associated with cardiometabolic disease. When administered in a safe and supportive setting, these drugs can cause neurogenesis, which strengthens and creates new neural pathways in the brain. Neurogenesis can help users form new positive associations and engender new modes of thinking that can lead to the adoption of positive lifestyle changes.

During the study, Simonsson also reported that psychedelics have strong anti-inflammatory properties as well as immunomodulatory properties. These anti-inflammatory properties could be a factor in psychedelics’ purported ability to fight cardiac disease. Coupled with their known effects on the body’s serotonin systems, this could indicate that traditional psychedelics are a strong candidate for developing new heart disease treatments.

“Lifetime classic psychedelic use was uniquely associated with a 23% lower odds of heart disease in the past year and a 12% lower odds of diabetes in the past year. Among the three main classes of classic psychedelics, neither lifetime tryptamine use, lifetime LSD use, nor lifetime phenethylamine use was uniquely associated with heart disease or diabetes in the past year when simultaneously entered into the regression models, though the association between lifetime tryptamine use and diabetes in the past year approached conventional levels of significance.” — Simonsson, O., Osika, W., Carhart-Harris, R. et al. Associations between lifetime classic psychedelic use and cardiometabolic diseases. Sci Rep 11, 14427 (2021).

While not concrete, these initial results provide an excellent argument for further study into the potential health benefits of using psychedelics. This research also aligns with results gathered by Dr. Steve Mandel, President of the American Society of Ketamine Physicians, who has treated over 600 patients with low dose ketamine infusions, nearly all of which have reported making positive health and life changes after treatment.

If shown to be effective, psychedelics could present novel new treatments for cardiometabolic diseases, such as heart disease and diabetes, which are among the leading causes of death in the United States and around the globe. Unfortunately, the current Schedule 1 Status of psychedelics like psilocybin and LSD make it difficult for researchers to conduct studies.

However, other traditional psychedelic substances such as ketamine have been approved for human use by the Food and Drug Administration and have been used everywhere from hospitals to battlefields since 1970. While there have been few studies directly linking ketamine use to reduced rates of heart disease, it is an exciting potential avenue of research given the relative ease with which researchers can obtain the drug.

David Connell is a U.S. Air Force Veteran writer and author of Cooking with Magic: The Psilocybin Cookbook. David holds a B.A. in Communications and Creative Writing from the University of Tennessee, Knoxville. Connect with him about drug policy reform, his thoughts on research in novel psychedelic therapies, creative writing, and his unabashed love for Science Fiction on Twitter, LinkedIn, and Instagram.

Source:

Simonsson, O., Osika, W., Carhart-Harris, R. et al. Associations between lifetime classic psychedelic use and cardiometabolic diseases. Sci Rep 11, 14427 (2021).
https;//doi.org/10,1038/s41598-021-93787-4

Dispelling the Stigmas, Ketamine, and the Future of Mental Healthcare

“Special K,” “Kitty Kat,” and “K” are all common street names for the prescription medication ketamine. Long used as a safe and highly effective anesthetic since the 1970s, ketamine gained popularity in the late 80s and early 90s as an underground club drug. This trend of adult recreational use has continued into today’s festival and rave scenes, where thousands of Americans use it annually as a “party” drug.

The drug’s popularity among recreational users stems from its entheogenic and hallucinogenic effects, which users say induce feelings of calmness, love, connection with the world and their loved ones, as well as euphoria. Ketamine has strong dissociative effects when abused and can be incredibly hallucinogenic in high doses. This psychedelic, dissociative state, popularly known as a k-hole, makes the drug attractive for some users.

However, adult use of ketamine can have a darker side. Ketamine abuse has been known to cause long-lasting damage to the central nervous system, dissociation, mental fog, and nausea. In some extreme cases, ketamine has also been responsible for users developing the extremely rare condition, hallucinogen persisting perception disorder (HPPD).

HPPD is a little understood and chronic mental health condition that causes sufferers to relive the psychedelic and dissociative effects of the drug in “flashbacks.” These flashbacks cause people with the condition to experience symptoms like visual distortions, audio hallucinations, whole body tingling, euphoria, and dissociative states. While this is concerning, HPPD is very, very rare, affecting less than 1% of all recreational substance users.

Unfortunately, this misuse of an otherwise legal anesthetic has led to ketamine developing a bad wrap with the general public. This bad wrap is particularly problematic for healthcare providers and researchers trying to expand ketamine’s FDA-approved usage from just anesthetic and analgesic treatments to depression, anxiety, PTSD, and other mental health and chronic pain needs.

This push by medical experts to expand ketamine’s approved list of uses comes from research started in the early 2000s that indicates ketamine has significant potential to treat conditions such as depression, PTSD, anxiety, and their treatment-resistant counterparts as well as chronic pain and substance abuse disorders. Compared to common depression treatments such as SSRIs, which only have a 35% efficacy rating, ketamine commands an impressive 70% effectiveness in reducing patient symptoms.

While that alone is impressive and warrants further research, ketamine has also shown a similar efficacy for treating PTSD, anxiety, and chronic pain. Ketamine is so effective that many providers have begun using it off-label to treat these conditions despite not having full FDA approval.

Despite ketamine’s vast array of potential uses, many stigmas and much misinformation about the drug continue to persist.

Stigma 1: Ketamine is Not Just an Animal Tranquilizer

One of the most common stigmas surrounding ketamine is its use as an animal tranquilizer. While it is true that ketamine is used in veterinary practices as an anesthetic, the dosages and best practices differ widely when compared to approved medical use for humans. For example, a common myth is ketamine was developed as a horse tranquilizer. This is not true.

Ketamine was originally developed by and tested by Corssen and Domin (1966) as a human anesthetic. It quickly moved through human trials and received FDA approval in the United States in 1970. From there, hospitals rapidly picked up ketamine as an alternative to other anesthetics. This quick adoption was due to ketamine’s low instances of side effects and the fact that ketamine does not suppress respiratory functions, a common problem with other types of sedatives.

Starting in 1971, ketamine was also deployed to the battlefields of the Vietnam conflict as both an anesthetic and an analgesic. The Department of Defense (DOD) adopted it for various reasons, including those covered earlier and ketamine’s low risk of dependency vs. opioid and opiate-based pain killers like morphine.

During the Vietnam conflict, morphine dependency became a significant problem for the United States military. With many service members developing crippling addiction to the potent opioid. These dependency issues among service members propelled ketamine’s adoption as a battlefield analgesic and an anesthetic used in field hospitals during the conflict.

Today ketamine is still widely used in hospitals across the U.S. Recently, it has also seen adoption among some providers to treat mental health and chronic pain conditions. For example, IV and nasal spray ketamine treatments for depression have gained widespread support, with a large and growing body of evidence showing the drug is both very safe and therapeutic.

Compared to depression medications such as SSRIs, ketamine has an efficacy rating of 70% vs. 35%. This astounding efficacy shows ketamine to be vastly more potent and effective at reducing depression symptoms. This potency also carries over to PTSD and anxiety treatments, as well as chronic pain conditions.

Stigma 2: Ketamine, Not a Highly Addictive Club Drug

“The medical benefits of ketamine far outweigh potential harm from recreational use.” —Marie-Paule Kieny, Assistant-Director General for Health Systems and Innovation at WHO.

While it is true that ketamine is used recreationally by thousand of people in the U.S. and possibly millions worldwide, it is not true that ketamine is only a club drug. The fact is that ketamine is a widely used and very popular anesthetic in hospitals across the globe. Ketamine is the preferred anesthetic for patients with respiratory conditions that put them at greater risk of breathing problems during surgery and is also favored for its low risks of dependencies vs. or drugs like opiates and opioids.

Ketamine is also the go-to anesthetic for use with children. Children are much more susceptible to the adverse respiratory effects of common anesthetic drugs, making ketamine the go-to choice in pediatric hospitals around the globe.

Compared to a wide range of other drugs among recreational users, ketamine users are significantly less likely to become addicted to the drug. Among regular recreational users, only 0.1 to 0.2 of adult users are likely to develop a dependency on the drug. This information aligns with medical community statistics that show similarly low instances of addiction from clinical and hospital use of ketamine.

If we compare ketamine addictions to legal drugs like alcohol, we can see that ketamine is significantly less likely to cause addiction. For example, six percent, or 20,030,687 Americans, will experience alcohol dependency throughout their lives. In contrast, less than one percent of the one percent of Americans that use ketamine recreationally will develop a dependency.

This misconception around the risk of dependency from ketamine use both clinically and otherwise is partly driven by media sensationalism and lingering effects of lousy science developed for messaging efforts as part of the War on Drugs. Of course, none of this means recreational use is without risks or should be encouraged. Still, myths and misinformation around ketamine must be dispelled if research and adoption of the drug for mental health and chronic pain conditions are to expand.

It’s time to change how we think about ketamine.

Ketamine is a powerful new tool for providers around the nation and the world to use in the fight for better mental healthcare. In the United States alone, over 8,900,000 men, women, and children will be diagnosed with some form of depression. Of those, 30% will not respond to treatment, and nearly 840,000 will try to commit suicide. SSRIs and similar drugs are not as effective as needed, and it’s past time for a change.

Research shows that ketamine will help seven in ten patients experience rapid onset relief from the symptoms of major mood disorders in as little as a single ketamine infusion session. When paired with psychotherapy, ketamine is staggeringly effective at treating some mental health conditions like PTSD and has even shown potential use for treating substance abuse disorders.

While ketamine is not a panacea, evidence shows that it is a highly effective and relatively low-risk treatment option for depression, PTSD, anxiety, and other disorders that millions of us are living with. Unfortunately, research into ketamine’s uses, like many other psychedelic drugs, is hampered by negative public sentiment and misinformed elected officials. It’s critical that this status quo changes and rapidly.

Join the conversation about the clinical use of ketamine and other psychedelic drugs, and help end the stigma around these potent weapons in the fight against poor mental health.

David Connell is a U.S. Air Force Veteran writer and author of Cooking with Magic: The Psilocybin Cookbook. David holds a B.A. in Communications and Creative Writing from the University of Tennessee, Knoxville. Connect with him about drug policy reform, his thoughts on research in novel psychedelic therapies, creative writing, and his unabashed love for Science Fiction on Twitter, LinkedIn, and Instagram.

Sources:

Carboni, E., Carta, A. R., Carboni, E., & Novelli, A. (1AD, January 1). Repurposing ketamine in depression and related disorders: Can this enigmatic drug achieve success? Frontiers. Retrieved December 16, 2021, from https://www.frontiersin.org/articles/10.3389/fnins.2021.657714/full

Green SM;Denmark TK;Cline J;Roghair C;Abd Allah S;Rothrock SG; (n.d.). Ketamine sedation for pediatric critical care procedures. Pediatric emergency care. Retrieved December 20, 2021, from https://pubmed.ncbi.nlm.nih.gov/11493822/

Communications, N. Y. U. W. (2021, October 7). Recreational ketamine use has increased in recent years, but remains rare. NYU. Retrieved December 20, 2021, from https://www.nyu.edu/about/news-publications/news/2021/october/recreational-ketamine-use.html

Hermle, L., Simon, M., Ruchsow, M., & Geppert, M. (2012, October). Hallucinogen-persisting perception disorder. Therapeutic advances in psychopharmacology. Retrieved December 20, 2021, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736944/

Li, L., & Vlisides, P. E. (2016, November 29). Ketamine: 50 years of modulating the mind. Frontiers in human neuroscience. Retrieved December 20, 2021, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126726/#B41

A First of its Kind: Wellbeing Digital Sciences Delivers its “First Ketamine Treatment Under the Inpatient KITE Program”

Gores Landing, Ontario – Wellbeing Digital Sciences, formerly KetamineOne Capital Limited, has officially announced the successful launch of its first intravenous “IV” ketamine treatment at the Victoria Wellness Mental Health Residential and Addition Treatment Centre (also referred to as “VW”) in Ontario. This was able to happen through collaboration with iHealthOX, a powerful, data-driven healthcare platform that strives to transform the primary care experience for its members.

VW is making waves in the industry by being one of Canada’s first in-patient facilities to offer ketamine-assisted therapy. Wellbeing management shared that they hope to see an increase in successful IV ketamine infusions in the future thanks to the collaboration between VW, iHealthOX, and itself.

“The success of our first IV ketamine treatment in Canada in collaboration with VW and iHealthOX and Wellbeing is encouraged that ketamine-based treatments for mental health are becoming more commonplace. The Company has always wanted to make a positive and significant impact on mental health, and this brings us one step closer,” said Adam Deffett, Interim CEO of Wellbeing.

VW is a residential facility and mental health clinic that offer personalized therapy treatment programs for anxiety, depression, and post-traumatic stress disorder. Located at 5316 Lake Scenic Drive in Gores Landing, Ontario, VW has launched a first-class, best practice-based, six-week inpatient Ketamine Integrated Therapy Experience (“KITE”) program with the help of Wellbeing Digital Sciences.

The KITE program offers a structure that allows clients a unique opportunity to benefit from the fast-acting and medically supervised IV ketamine administration. It’s believed that this process will help combat treatment-resistant mental health conditions such as depression, anxiety, and PTSD.

VW’s KITE program is possible through the collaborative efforts of both Wellbeing and iHealthOX. The latter was created to help give patients a customized digital tool specifically curated for mental health. Patients can access live coaching sessions, evidence-based material, 24/7 emotional support, and options for one-on-one therapy. The platform will be available to patients via both desktop and mobile versions, effectively extending Wellbeing’s services beyond just its clinic locations.

Kaeli Swaggerty holds a B.A. in English from the University of Tennessee, Knoxville. Connect with her about bringing awareness to mental health issues on LinkedIn.

Source:
Wellbeing Digital Sciences Inc. “Wellbeing Digital Sciences Delivers Its First IV Ketamine Treatment under the Inpatient Kite Program.” GlobeNewswire News Room, Wellbeing Digital Sciences Inc., 15 Feb. 2022, https://www.globenewswire.com/news-release/2022/02/15/2384871/0/en/Wellbeing-Digital-Sciences-Delivers-its-First-IV-Ketamine-Treatment-Under-the-Inpatient-KITE-Program.html.

Aggregate Study on the Efficacy of Ketamine to Treat Depression Shows Promising Results.

A recent aggregate study on the effectiveness of ketamine treatments for depression conducted by Ezio Carboni, Anna Carta, Elena Carboni, and Antonello Novelli, and published by Frontiers in Neuroscience, shows ketamine has significant promise as a treatment option for chronic and treatment-resistant depression.

Ketamine, an anesthetic and analgesic drug first developed in the 1970s, has long been used in hospitals, clinics, and battlefields as a safe alternative to other anesthetics. Unlike other medications, ketamine does not depress the respiratory or circulatory systems of patients it is administered to; this factor has made it a go-to compound for surgical proceedings in hospitals worldwide.

Despite ketamine’s long and successful use as an anesthetic, it has only recently, within the last decade, started to gain notoriety as a breakthrough treatment for depression and substance abuse disorders. This recognition of ketamine’s potential for treating depression comes from its rapid onset and relatively low risk of severe side effects. Unlike traditional SSRIs that take several weeks or longer to begin working, ketamine has been shown to have a near-immediate impact on patients who receive the drug.

As reported by Carboni, ketamine and its derivative drug esketamine affect brain NMDA (glutamate) transmission. This impact on the available levels of glutamate is believed to be responsible for ketamine rapid antidepressant effects. However, research into this and other areas of depression treatment is hampered by a lack of available animal studies.

Carboni proposes that ketamine also significantly impacts other neural transmitters, such AMPA, BDNF, eEF2, and glycogen synthase kinase 3. All of which are thought to be partially responsible for depressive symptoms in patients. Furthermore, Carboni Et. Al. postulates that ketamine stimulating qualities also positively affect patients with depressive symptoms, particularly those with treatment-resistant depression.

This may be due to ketamine’s ability to alter background synaptic activity, changing how some synaptic pathways in the mind that have become locked into depression-related states transmit information. This rewiring of neural activity is thought to allow data to be processed in new ways, potentially relieving depressive symptoms.

Carboni shows that ketamine’s ability to break free locked in synapses was first noted in research conducted by Berman et al. in the early 2000s. Berman’s research showed that patients with depressive symptoms given ketamine showed significant improvement in as little as 72 hours. Notably, this rapid relief from depressive symptoms was not experienced by the control group who received a placebo only.

Furthermore, trials conducted by Yang et al., 2019a and Canuso et al., 2018 showed both esketamine (Spravato) and R-ketamine provide rapid relief to patients with treatment-resistant depression. Interestingly R-ketamine, while being less potent than esketamine, showed longer-lasting anti-depressive benefits and required less follow-up course of the drug to maintain its anti-depressive effects.

While research into ketamine and its derivatives is still relatively new, research and trials like those mentioned above show that the drug has strong therapeutic potential. Particularly for those with major mood disorders or treatment-resistant depression. One of the most critical aspects of research like that detailed in this article is its ability to inform the general public about these new tools in the fight against mental illness.

Unfortunately, the public has long viewed ketamine as a party drug, leading to widespread misinformation and stigma around its use. As knowledge about the benefits of drugs like ketamine and even other psychedelics grows, it will be critical that the people stay engaged and become part of the greater conversation around not just ketamine but mental health as a whole.

David Connell is a U.S. Air Force Veteran writer and author of Cooking with Magic: The Psilocybin Cookbook. David holds a B.A. in Communications and Creative Writing from the University of Tennessee, Knoxville. Connect with him about drug policy reform, his thoughts on research in novel psychedelic therapies, creative writing, and his unabashed love for Science Fiction on Twitter, LinkedIn, and Instagram.

Sources:

Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., et al. (2018). Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am. J. Psychiatry 175, 620–630. doi: 10.1176/appi.ajp.2018.17060720

Carboni, E., Carta, A. R., Carboni, E., & Novelli, A. (1AD, January 1). Repurposing ketamine in depression and related disorders: Can this enigmatic drug achieve success? Frontiers. Retrieved December 16, 2021, from https://www.frontiersin.org/articles/10.3389/fnins.2021.657714/full

Yang, C., Wardenaar, K. J., Bosker, F. J., Li, J., and Schoevers, R. A. (2019a). Inflammatory markers and treatment outcome in treatment-resistant depression: a systematic review. J. Affect. Disord. 257, 640–649. doi: 10.1016/j.jad.2019.07.045

Maryland Attempting to Pass Bill That Would Benefit Military Veterans By Providing Them ‘Cost-Free Access’ to Psychedelics

Maryland Senate recently filed a bill that, if passed, would create state funding for free access to psychedelics (psilocybin, MDMA, ketamine, etc) for military veterans who suffer from post-traumatic stress disorder (PTSD). The bill would also support the research of the therapeutic potential of psychedelics.

The purpose of the bill is to establish what’s known as the Post-Traumatic Stress Disorder Alternative Therapies Fund[1]. The money would fund research in psychedelics as well as provide “cost-free access to alternative therapies” for military veterans.

Additionally, the bill, sponsored by Sen. Sarah Elfreth (D), would require regulators to periodically “consult with the Department of Veterans Affairs, the John Hopkins University, the University of Maryland, Sheppard Pratt, and Walter Reed National Military Medical Center” on the use of psychedelics for PTSD treatment.

If the bill goes through and is received positively, then it could set the groundwork for future legislation on providing residents with regulated access to psychedelics for therapeutic use.

The bill currently has nine senators as cosponsors and is scheduled to receive a hearing during the state’s Budget and Taxation Committee on March 2 of this year.

In order for the bill to pass, the Maryland Department of Health would need to submit a report of “initial findings and recommendations” to the governor and legislation by December 1, 2022[2]. In two years’ time would come another deadline for findings and recommendations based on the studies that were conducted specifically through the PTSD fund.

Maryland’s proposal is just one of many as states move towards the decriminalization of psychedelics.

In a recent Ketamine News article, we covered how Washington State Sens. Jesse Salomon (D) and Liz Lovelette (D) are pushing to legalize psilocybin.

The movement to decriminalize psilocybin in the US originated in the late 2010s, with Denver, Colorado becoming the first city to accomplish its goal in May 2019. Oakland and Santa Cruz, California followed closely behind, both successfully decriminalizing psilocybin by January 2020.

In November of the same year, voters passed the Oregon Ballot Measure 109, effectively making Oregon the first state to decriminalize psilocybin while legalizing it for therapeutic use.

These efforts come in the aftermath of the rapid onset of cannabis legalization in the United States, occasionally referred to as the Green Rush[3].

According to an article written by Dustin Marlan for The Appeal, titled, “The Movement to Decriminalize Psilocybin, Explained,” he writes, “Psilocybin reform is an important development for at least two reasons. First, psilocybin is a promising compound that, if studied and used appropriately, can provide benefits to many. Second, psilocybin reform may spur a radical rethinking of the prohibition on other Schedule I substances, and can thus be a catalyst toward ending the racist and draconian War on Drugs.”[4]

More and more states are pushing for the decriminalization of psilocybin as studies have shown that it is an effective treatment option for depression, anxiety, and substance abuse.

Kaeli Swaggerty holds a B.A. in English from the University of Tennessee, Knoxville. Connect with her about bringing awareness to mental health issues on LinkedIn.

Sources:

“Maryland SB709.” TrackBill, https://trackbill.com/bill/maryland-senate-bill-709-post-traumatic-stress-disorder-alternative-therapies-fund-establishment-david-perez-military-heroes-act-end-22-a-day/2218272/#:~:text=Establishing%20the%20Post%2DTraumatic%20Stress,any%20other%20money%20from%20any.

Jaeger, Kyle. “Maryland Senate Bill Would Provide ‘Cost-Free Access’ to Psychedelics for Military Veterans.” Marijuana Moment, 9 Feb. 2022, https://www.marijuanamoment.net/maryland-senate-bill-would-provide-cost-free-access-to-psychedelics-for-military-veterans/.

Overland, Martha Ann. “The Green Rush Begins: Investors Get in on Pot’s Ground Floor.” NPR, NPR, 16 Feb. 2014, https://www.npr.org/2014/02/16/277691480/the-green-rush-begins-investors-get-in-on-pots-ground-floor.

“The Movement to Decriminalize Psilocybin, Explained.” The Lab by the Appeal, https://theappeal.org/the-lab/explainers/the-movement-to-decriminalize-psilocybin-explained/.

Ketamine Media Launches Industry Leading Psychedelic Therapy Network

KETAMINE MEDIA (LLC). is proud to announce the launch of their Psychedelic Therapy Network (PTN), a digital ecosystem linking psychedelic medicine providers to individuals seeking innovative new treatment options in the world of mental healthcare.

Psychedelic Therapy Network (PTN) is the culmination of a long endeavor to provide patients looking for alternative care with a single point of reference and comprehensive resource for finding psychedelic medicine providers in their regions. The collection of digital assets will effectively reach potential candidates in virtually every zip code across North America.

Ketamine Media felt that creating the network was not just something that would make patient lives easier but also a critical tool for spreading awareness and education about psychedelic medicine. With the nation facing the worst mental health crisis in its history, new methods and modalities of treating mental health conditions are needed.

“The Psychedelic Therapy Network was designed to assist our partners in effectively raising awareness at scale. But it’s really designed with patients in mind. When we created it [the Psychedelic Therapy Network], we wanted to take a patient-first approach. The psychedelic medicine space can be confusing, and our team wanted to build something that helps people learn more about psychedelic medicine and unites them with qualified, passionate providers once they decide that this approach is right for them.”
Chris Walden, CEO and Co-founder, Ketamine Media

Novel new drugs derived from compounds like psilocybin, MDMA and more will soon join existing therapies like ketamine-assisted psychotherapy to combat the country’s crippling mental health problems. Psychedelic therapies like ketamine have shown the potential to be more effective than standard medication such as SSRIs, with psilocybin and MDMA showing similar or greater efficacy. With that in mind, creating a single comprehensive network was seen as an essential part of laying the groundwork for the future.

Currently, the PTN primarily serves as a hub for patients to find providers specializing in various forms of ketamine-assisted therapy and infusions. However, as medications continue to gain approval, like MDMA (currently entering phase three trials conducted by MAPS) and psilocybin (entering phase two trials with COMPASS Pathways), the network will expand to cover medical providers offering those services as well.

Expanding access to novel mental health treatments can provide significant benefits to the general public but is vitally important to the nation’s veteran population. Military veterans and first responders are 52% more likely to develop post-traumatic stress disorder (PTSD), a mental health condition associated with traumatic experiences. Veterans and first responders are also significantly more likely to experience depression and have much higher rates of suicide than the general population.

“As a veteran who’s dealt with PTSD and depression first hand, I can say that treatments like psilocybin, ketamine, and MDMA do work. Unlike many veterans, I’ve had the opportunity to experience the healing potential of psychedelics firsthand at retreats in legal countries. If veterans here at home (The United States) had access to this sort of therapy, we would likely see a significant reduction in veteran suicides and depression rates across the board.”
David Connell, Author, Cooking with Magic: The Psilocybin Cookbook and Senior Copywriter at Ketamine Media.

The potential benefits of psychedelic medicines go beyond veteran mental healthcare. End-of-life care, treatment-resistant depression, anxiety, and substance abuse disorders are just a few of the conditions that psychedelic compounds have shown promise for treating.

Tools like the Psychedelic Therapy Network will be an essential part of growing the reach of psychedelic medicine providers as therapies such as ketamine-assisted psychotherapy, MDMA-assisted therapy, and psilocybin treatments gain notoriety. Patients and providers will benefit from the suite of tools, connections, and educational resources offered by the PTN, furthering public awareness and knowledge regarding these potent tools for combating mental health conditions.

ABOUT KETAMINE MEDIA (KETA MEDIA, LLC)
Ketamine Media is a full-service multi-media marketing and advertising agency headquartered in Knoxville, Tennessee. Specializing in raising awareness about the clinical use of ketamine and other psychedelic medicine, Ketamine Media is the nation’s oldest and highest performing ketamine-focused advertising agency. Ketamine Media’s team offers a wealth of experience communicating with and connecting to individuals interested in exploring novel treatments for their mental healthcare. This specialized know-how is invaluable for their partners within the space, who need to reach patients in critical need of specialized care. If you are interested in partnering with Ketamine Media, the company can be contacted at:

Ketamine Media
611 King St NW
Suite 200B,
Knoxville, TN 37917

Phone: (800) 975-2291
Online: https://ketaminemedia.com

Peter Thiel-Backed Psychedelics Company Gets FDA Approval To Study Ketamine Therapy

The U.S. Food and Drug Administration has authorized German psychedelics startup Atai Life Sciences to conduct a clinical trial on a nonpsychedelic form of ketamine for treatment-resistant depression.

The company will study R-ketamine, an enantiomer of ketamine, the FDA-approved dissociative anesthetic that is used for general anesthesia and off-label as a popular treatment for depression.

R-ketamine’s promise is that it may not produce a psychedelic experience while still providing rapid antidepressant effects. If proven in clinical trials, R-ketamine could be a new medication for people with treatment-resistant depression and safe enough to use at home, not in a clinic under medical supervision like ketamine and Spravato, another form of the drug that has been approved by the FDA.

Atai’s majority-owned subsidiary Perception Neuroscience will launch the first in a series of clinical trials on R-ketamine early this year in the U.S. The first trial will be a drug interaction study.

Florian Brand, the CEO and cofounder of Atai, which is backed by billionaire Peter Thiel and is publicly traded on the Nasdaq, says that if the trials successfully show that R-ketamine is a fast-acting antidepressant safe enough for at-home use, it “would be a big game changer for patients.”

Perception Neuroscience has already launched two studies on R-ketamine abroad.

The phase 1 trial, which was conducted in New Zealand with 58 adults who received different doses of an intravenous infusion of R-ketamine in February, found that their compound, which they refer to as PCN-101, was “safe and well-tolerated” at all doses up to 150mg. Participants reported no serious adverse effects. The second stage of the study compared PCN-101 to S-ketamine, which is the ingredient in Spravato. The results showed that Perception’s compound required substantially higher doses to induce similar psychedelic experiences than S-ketamine.

In September, Perception was approved to launch a double-blind, placebo-controlled phase 2a trial in patients with treatment-resistant depression in Europe. The study plans to enroll 93 patients who will receive either a placebo, a 30mg dose or a 60mg dose of R-ketamine, which will be given intravenously. The trial will be studying if the drug is safe and effective in reducing depressive symptomology. Results should be ready by the end of 2022.

Terence Kelly, the CEO of Perception Neuroscience, which is based in New York, says that he is encouraged by how R-ketamine is progressing through the regulatory process. “We believe that PCN-101 has the potential to offer a differentiated therapeutic effect, in terms of both efficacy and ease of administration, for clinicians and patients,” Kelly said in a statement.

Srinivas Rao, Atai’s chief scientific officer, says that the psychedelic experience is important for many of the drugs the company is pursuing, but R-ketamine’s nonpsychedelic properties is what makes it a potential disruptive medication for treatment-resistant depression.

“At-home use—that’s the key,” says Rao. “Everything else that we’re looking at, like psilocybin, must be administered in the doctor’s office. This is obviously important for those compounds. But if we can get something that can be administered at home as a rapid-acting agent, that’s a potential much larger market and certainly broadens the appeal of the compound.”

Big Pharma has already taken interest in R-ketamine. In March 2021, Otsuka Pharmaceutical announced a $20 million licensing agreement to develop and commercialize Perception’s R-ketamine compound in Japan as a potential treatment for major depressive disorder and treatment-resistant depression. Otsuka will have exclusive rights to PCN-101 in Japan. If Otsuka successfully brings the drug to market, Perception will receive royalties on sales.

The opportunity for a new blockbuster medication to treat conditions like depression, anxiety and post-traumatic stress disorder is huge. Prescription sales for depression is estimated to be $50 billion a year globally, while the mental health market is worth about $100 billion in annual sales. While biotech analysts say that FDA-approved psychedelic-assisted therapy could seize $10 billion in annual sales by targeting the treatment-resistant depression subcategory, the real opportunity lies in replacing drugs like Prozac, Zoloft and other selective serotonin reuptake inhibitors.

An estimated 100 million people have treatment-resistant depression around the world, which is a sizable market for R-ketamine.

“What excites us, certainly, is what you call blockbuster potential,” says Brand. “We’re really interested in large unmet needs, large markets, large opportunities.”

Atai is also the largest investor in Compass Pathways, a U.K.-based clinical stage company that is developing a patented form of psilocybin to be used in conjunction with therapy for treatment-resistant depression. In November, Compass Pathways’ much-anticipated FDA-approved phase 2b clinical trial found that patients who took a single psychedelic dose of psilocybin, the main ingredient in “magic mushrooms,” in conjunction with therapy reported almost immediate and significant reduction in depressive symptoms that lasted weeks compared with patients who were given a 1mg dose, which is so low it’s essentially a placebo. 

Atai, through another majority-owned subsidiary, is building a suite of second-generation psychedelics that feature a shorter-lasting two-hour trip.

Brand says that when it comes to treatments that involve a psychedelic experience, the length of the psychedelic experience itself is an obstacle to mainstream adoption.

“We’re all about scale,” says Brand.

By modifying psychedelic molecules to shorten the trip, more patients might try it and insurance companies could be more willing to cover the treatment.

Brand and many others in psychedelic medicine believe that the no-trip treatment will have a prominent place in the future of the industry.

“We have a vision for precision psychiatry,” says Brand. “Ultimately, the goal is to identify which type of treatment is the right one for which patient. Not everyone will necessarily always want to do psychedelic agents like psilocybin. For some, it might be the appropriate treatment, but it’s not really feasible for everyone.”

Rao says the future is in choices. Finding a medication that helps patients with treatment-resistant depression is particularly difficult considering that these patients have tried many different drugs without success. About 30% of people with depression find no success with available treatments. Rao says if R-ketamine is approved it would become another tool doctors can use.

“It depends on where you are in your disease process—you may need esketamine, or you may need psilocybin or DMT, or something else to induce and then you could maintain with R-ketamine,” says Rao. “But we don’t yet know how things will shake out.”

Ketamine, Psilocybin and the Rise of Missouri Psychedelics

Inside the salt room, Scott Mickey flew above the bright expanse of his own consciousness. His eyes were closed. A weighted blanket pressed his body into a recliner. In his arm, an IV delivered a few dozen milligrams of ketamine to his bloodstream.

His mind was somewhere else.

“I ain’t gonna lie, I was very skeptical,” recalls Mickey, a 45-year-old business owner who runs a chain of head shops in rural Missouri. Before ketamine, the Rolla native had spent much of his life gripped by a deep social anxiety that made crowded indoor spaces, even a trip to the grocery store, intolerable to the point of breakdown.

He had gone to a psychiatrist. They prescribed him the antidepressant Xanax, but he says it felt like “wrapping your head in a blanket.” So, one day this past October, he went to a different doctor, one located in a compact strip mall opposite the Saint Louis Galleria in St. Louis.

Ketamine is undergoing something of a renaissance. First synthesized in 1962, the substance has been used for decades as a surgical anesthetic, and not just because of its ability to safely render a person unconscious. For reasons scientists are still studying, the introduction of ketamine releases the mind to dissociate — that is, to be blissfully unaware, in all sensation and memory, of the physical trauma happening to their body.

However, with smaller amounts of ketamine, a person can experience that disassociation without the amnesia. That experience, as shown in the growing body of scientific research and widening availability of treatment options, acts as a profoundly effective antidepressant.

But it’s not just ketamine that holds such promising possibilities for treatment. Currently, a combination of state and federal laws block patients from using an even more powerful line of psychedelics, substances that have long been used in indigenous rituals and which are well known to the crowd of self-experimenting “psychonauts” for their mind-expanding effects.

For Mickey, attending music festivals in his twenties had brought him into contact with hallucinogens like LSD and magic mushrooms, but it had been many years since he had taken a psychedelic trip. That day at the clinic in St. Louis, as the salt vapors flowed, he found himself settling into a comfortable chair and listening to the music coming from the wall speakers, the melody soft and meditative.

“I was sitting there, they started the IV, and I just got this little bit of a tiredness that came over me,” he says now. “It was like, ‘Oh, I could probably lay back and get comfortable.’ When I laid my head against the pillow, it was like a light switch. It was, boom, there I was, flying. And there was no fear to it.”

He remembers looking down at an endless landscape beneath him. He says, “I started thinking about my anxiety — why do I get uncomfortable in various situations? I flew close to the ground and saw this dark spot in the center of this snow-covered region. I instantly knew that it was either trauma or something that had happened in my life that created that inside of me.”

As easy as thinking, Mickey flew down to the dark spot, and “exchanged energy.” The spot turned light, and, he says, “as it happened, I would feel the release of this incredible weight.”

Today, he describes it as one of the most powerful sensations of his life. He was sold.

“Once I had tried it once, I was like, ‘Alright, I’ll take the package.'”

After decades of legal restrictions and fear mongering, Americans are finally coming around to the notion that psychedelics are legitimate medicine. Even as the law and science lag behind, people in Missouri like Scott Mickey are already embracing ketamine; and these aren’t hippies or followers of the sort of LSD utopia envisioned by Timothy Leary in the 1960s — these are simply people in pain.

During a recent visit to the Radiance Float + Wellness clinic in Richmond Heights, psychiatrist Dr. Zinia Thomas walks through a short hallway to the salt room, the same room in which Scott Mickey tuned in, dropped out and started flying through his mind. The back wall, built of rock salt bricks, is lit with cool blue lights. A flier on a table features a friendly message, “Enjoy your K-Cation,” beneath a photo showing a line of multicolored cottages on a perfect beachfront.

Thomas founded the clinic in 2017, one year before then-President Donald Trump signed the federal Right to Try Act that made some classifications of drugs, including ketamine, open to therapeutic use if patients had exhausted FDA-approved treatment options.

At first, Thomas says she considered ketamine treatments as an option of last resort. But two key events shaped her current stance that ketamine is for everyone.

First came Missouri’s legalization of medical cannabis. In 2020, Thomas began prescribing medical marijuana licenses to hundreds of patients across the state through virtual appointments. Quickly, she says, it became clear that people were seeking more substantial relief than even high-potency cannabis could offer.

“They wanted it to cure their depression, PTSD, their pain, migraines. They wanted it to cure everything,” she says. “People put so much hope in it, but this is just a plant.”

Thomas says she began suggesting ketamine as a possible treatment for her medical marijuana patients’ more serious health needs. Around the same time, the pandemic hit — and with it, the crush of isolation, job stress and the ever-present tragedy of the rising death toll. She believes the pandemic inflamed a mental-health crisis that was already burning out of control.

“Even high-functioning people have suffered so much loss in the pandemic,” she notes. “I just thought, ‘Why should you have to fail other antidepressants before trying something like ketamine?'”

Finding the Light at the End of the Tunnel with Advanced Wellness and Pain

“The light at the end of the tunnel” is a phrase I found myself turning to much more frequently since 2020. Nobody is walking out of the events of the last 18 or so months unscathed, but the hope is that we emerge wiser for the wear.

The problem with the light at the end of the tunnel is that, by definition, you rarely see it when you embark on this journey. You have no choice but to dive headlong into darkness, hoping that the light will be there to greet you soon.

There’s no sugar-coating it: this is hard – to get in the car, fasten your seatbelt, put the keys in the ignition and depart without any sense of where you’re going or who you’ll be when you get there. It’s during these times we most often could use a hand.

Not a helping hand; no, we can make it ourselves. Not a guiding hand, either – the road is long but we know we’re on the right path. What we need most is a handshake, someone who’s been down this road before who can assure us that, yes, it is difficult but in time we will emerge on the other side bathing in the light of new hope that was once just a far-off glimmer.

That, more than anything else, is the goal of the providers at Advanced Wellness and Pain. It was made abundantly and refreshingly clear to me over our recent Zoom call – the new normal, it seems – that their mission is to create a treatment center that patients can trust. Trust not just to be experts in their fields, but also trust to know they have been there, and they understand.

Advanced Wellness and Pain was born out of its founders – James Leathem, DO, Gregory Wong, MD, and Deepak Sharma, MD, MBA – and their understanding that 2020 exposed us to the gaping wounds of our healthcare model; their understanding that not only do we need new treatments, but most importantly we need providers who understand them and how they make patients feel.

Continue reading for our full conversation about their backgrounds, their commitment to patient care, and the new clinic facility they have moved to.

What separates Advanced Wellness and Pain from other clinics?

First, we are three board-certified physician anesthesiologists who directly participate in each patient’s care. We intake each patient and directly administer the ketamine ourselves. In addition, we optimize dosing both during and between infusions. We will often micro-bolus patients during their infusion to achieve optimal ketamine experiences in our clinic. Then, depending on the patient, we will escalate our dosing to achieve dissociative experiences by their 5th or 6th infusion.

The most important distinction is that we have worked tirelessly to create a comprehensive integrated program that helps our patients create life-long results for their mood, chronic pain, and substance abuse disorders. Furthermore, we have a unique partnership with a psychedelic integration coaching company. We are the only ketamine clinic in the state of Arizona with this partnership. They are experts in psychedelic integration and help our patients prepare, process, and integrate their ketamine experiences into their lives. We also collaborated to author a ketamine preparation and integration workbook that combines our knowledge and expertise. This helps to create a more consistent experience for our patients and encourages them to be an active participant in their healing journey. 

This is key for immediate and long-term results. It’s common for patients to be confused with some of the ideas they encounter during or after their infusion sessions. Our coaches are able to help clarify and assist our patients by insightfully unpacking their revelations in the 24-48 hours post-infusion. Coaching them with integrative and cultivative techniques are critical and necessary for sustained results. On top of that, we teach meditation, mindfulness, breathwork, journaling, visualization, and other life hacks to sustain a positive mindset. This has allowed us to create a success rate of over 95%, compared to the reported national average of 70%.

How much time do you spend taking care of each individual patient?

The time involved for our first infusion session is two hours, subsequent sessions are one-and-a-half hours. In addition, there are three hours of 1:1 integration coaching. The induction or stabilization phase of six infusions, over the course of two to three weeks, involves over 12 hours of time with each individual patient.

What can you tell me about your commitment to patient care?

Our commitment to patient care is unprecedented and another key to what sets us apart from other facilities. Not only is our set and setting pushing beyond typical expectations, but our patients have messaging access to us at any time of the day as part of our program. They will have two, often three physicians interacting with them during any visit. We converse with our patients before starting each infusion and after each infusion to help them optimize their sessions.

There is a lot of excitement around our ongoing clinical study for first responders affected by PTSD that started earlier this year and should be completed by this year’s end. The early data has been fantastic and we should be publishing our results soon.

How does the new office facility help you treat your patients?

We just built a brand-new beautiful state-of-the-art clinic in Scottsdale, Arizona. It was designed specifically for ketamine infusion treatments in order to optimize the patient’s setting, which is crucial to the experience. We have five private rooms with integrated healing music, LED color lighting, vibro-acoustic meditation cushions, zero-gravity chairs, and exquisite artwork. We have created the safest setting for our patients to heal from within.

Can you each tell me a little bit about your background and expertise?

James Leathem, DO

 I completed my Osteopathic Medical Degree at Midwestern University in Glendale, Arizona in 2011. I have been an anesthesiologist since 2015 and trained at Michigan State University. In hindsight, I was lucky to have trained at a very ketamine-centric program. Not all anesthesia programs embrace the use of ketamine equally. We embraced a multimodal approach and ketamine was often part of the anesthetic plan. That is the beauty of anesthesia, it is both an art and a science. In my professional opinion, I think ketamine often improves the anesthetic picture for the patient.

When I was a medical student, having to decide which specialty to pursue, I was conflicted between anesthesiology, family medicine, and psychiatry. Ironically, what I do now is essentially a merger of those three fields. I have administered ketamine to thousands of patients in my career, perfecting my understanding of its dosing and pharmacodynamic effects.

I do a thorough medical history on my patients so I can better understand them from a bio-psycho-social-spiritual point-of-view. I have a passion for exploring consciousness and helping others to evolve their perspective. I also recently became a certified psychedelic integration coach in order to strengthen my ability to care and connect with my patients.

I realize we are all a work-in-progress and societally we are amidst a mental health crisis in the United States. I want to be a part of the solution by catalyzing the healing of patients through the careful administration of psychedelics, ketamine being the only currently-legal psychedelic. We are likely to see a lot of changes in the next two-to-four years involving psychedelic medicines, also known as entheogens, due to the tireless efforts of MAPS.

These are exciting times and I feel fortunate, through the use of my knowledge and skills, to play an integral role in the healing journeys of my patients. Providing hope and attaining positive results for those that have tried so many other options and have been labelled as “treatment-resistant” is truly fulfilling.

Deepak Sharma, MD, MBA

I completed a dual degree in medicine and business at Drexel University in Philadelphia in 2012. I did my residency training at Mount Sinai Morningside-West Hospital in New York City and have been an anesthesiologist since 2016. In my training, we frequently administered ketamine infusions in the operating room as a multimodal approach to managing surgical pain. Patients required significantly less amounts of opioids to control their pain after surgery because of ketamine. 

Our pain management service also administered ketamine infusions to treat patients with Complex Regional Pain Syndrome (CRPS). Most of these patients had accompanying mental health problems, such as anxiety and depression. They would notice that after ketamine infusions, not only would their pain reduce, but their anxiety and depression would also diminish. Had I not been exposed to the powerful benefits of ketamine in my training, I would likely not have gone down this path of becoming a psychedelic medicine physician today.

Unfortunately, most practitioners don’t get enough exposure to ketamine so they have misguided opinions about its value. Even more unfortunately, I’ve found in my career as an anesthesiologist that the healthcare industry has misguided opinions about the value of anesthesiologists and physicians as a whole.

After working in multiple large organizations, both corporate and academic, I realized that I was just a cog in the wheel of a massive machine. I had very little autonomy over how I practiced and I was constantly under pressure to produce. Quantity mattered more than quality to the CEOs. This is the current state of healthcare: big conglomerates merging to form even bigger entities; controlled by private equity forms; managed by bloated administrative staff; with doctors, nurses, and other providers serving as the labor force.

But most of us providers put up with it because of the competitive salary. Kevin O’Leary, a prominent businessman and television personality on Shark Tank, once said that “a salary is the drug they give you to forget your dreams.” That phrase really stuck with me. Although I’ve given up the comfort of a salary to start this venture, I feel much more spiritually satisfied that I’m part of this revolutionary psychedelic movement and that I’m helping to build a resource for struggling patients.

I’ve struggled in many instances in my own personal life, and I know how it is to feel incapacitated from stress, anxiety, and depression. In fact, residency was so stressful that two of my colleagues I trained with committed suicide. It was through my own journeys with psychedelics that I was able to gain a new perspective on life and be resilient enough to persevere through adversity.

My mission now is to show others this new perspective. Helping others navigate through their mental blocks and potentially saving lives in the process is exactly what I want to be doing.

Gregory Wong, MD

I graduated from the Chicago Medical School in 1992 and completed my anesthesia training at the University of Arizona in Phoenix in 1996. I trained using ketamine frequently during high risk obstetrics cases. Although many people believe that ketamine is a dangerous drug, it is actually one of the safest anesthetics that we have available to use. Ketamine’s safety profile makes it one of the preferential drugs during emergency surgeries. 

Over time, us anesthesiologists found secondary benefits that began showing up during patient’s times of stress. We discovered that at low doses of ketamine, patients’ pain syndromes as well as depression were improved. The secret is that when ketamine is used at low doses, it partially blocks the NMDA receptor. This has a very different effect than when given at large doses as in a typical anesthetic. It literally causes neuroplasticity, or new neural pathways.

When used properly, this allows our patients to heal from within. As we have all become more aware of the mental health and substance abuse crisis in our country, I believed it was important for me to take an active role as a physician leader for a solution. The ability to shape the future of patient care through psychedelic medicine is both an intriguing and extremely rewarding practice. We are in the middle of a paradigm shift in mental health care.

We are offering our patients the chance of healing and repairing past emotional traumas with our ketamine-based wellness program. It is unlike typical pharmacologic antidepressants and central nervous system medications that function more like a band-aid than a healing process. Although quite a few ketamine clinics have opened up over the last two or three years, we are still at the infancy of psychedelic medicine. The clinical trials of MDMA and psilocybin show us that new legal compounds will be available in the next two-to-four years.

Our clinic’s plan is to demonstrate how these compounds are even more useful when combined with an integration process. This is precisely why we launched our own clinical study using ketamine and integrative coaching for PTSD patients over a multi-month time frame. For this reason, I feel we run one of the top ketamine clinics in the country. We have scrutinized every aspect of the process and worked to optimize the patient experience.

The results have produced an amazingly high success rate of over 95%. This is well above the national average, so I know our clinic is performing at a very high level.

What led you to start a ketamine clinic?

Our anesthesia business slowed down quite a bit during the COVID crisis in 2020. We saw the amount of mental health illness rising in our country. We looked at the landscape of care and thought we could do an exceptional job of taking care of patients with ketamine, since we were all experts using ketamine in our combined 40+ years of clinical anesthesia practice. We saw that mental health/depression is predicted to be the leading cause of disability by 2030. This led us to believe that we could be leading contributors to shaping psychedelic medicine treatment in the future and evolving the paradigm surrounding mental health care.

What lessons have you learned about mental health during your time at Advanced Wellness and Pain?

We learned that there are a lot of people suffering with their mental health and COVID exacerbated the problem for many. We also learned that most ketamine clinics are not supporting their patients optimally during their acute phase of care. Most do not offer services beyond just the infusion of ketamine itself.

Ketamine is not a magic bullet. Rather, it is a powerful tool and catalyst to healing when set and setting are optimized, the ketamine is precisely dosed, and the patient receives proper preparation and integration coaching. We have had several patients receive care from us after having received ketamine infusions elsewhere. They all resoundingly confirmed we have a truly unique process.

We realize that having strong mental health is a result of conscious daily practice. You have to be an active participant in your healing. Just like we need a good diet and exercise to optimize  our physical health, we need a good diet and exercise for our mental health. In this case, diet is composed of our social media feed, news, screen time, human interactions/relationships, nature exposure, sleep and consumption of psychotropic substances; and exercise is daily meditation, mindfulness, breathwork, activities, guided journaling, and recognizing your internal narrative.

We also offer patients infusions of essential vitamins, minerals, anti-oxidants, and NAD+ to further optimize the patient’s internal milieu as they heal.

We personally guide our patients through this often anxiety provoking or confusing foreign process. It is paramount to a patient’s success. Asking a patient to navigate their subconscious when they have debilitating depression or general anxiety is a huge task to ask someone to conquer on their own.

What should I ask you about that I didn’t know enough to ask?

A question that many people probably wonder about a physician who administers ketamine to help others heal would be, “have you ever tried the infusion yourself?” The short answer is yes. You can only lead someone as far as you have gone yourself.

In our professional opinion, you can read about ketamine all you want. Unless you have personally experienced it in an optimized safe-setting, you will not fully understand its effects on the mind and its healing potential. It is our understanding that less than 10% of ketamine practitioners have in fact tried an infusion themselves. Maybe most won’t be honest and admit it. Maybe it’s higher than 10%.

Regardless, if I were a patient, I would want to go to a doctor who has actually journeyed with the medicine. Otherwise, how do you truly relate? The experience at times is ineffable. Would you take swim lessons from an instructor who can’t swim? I think not. In our professional opinion, you must have walked the walk in order to fully understand the unique healing potential of ketamine and the potentially transformational impact of the psychedelic medicine renaissance that is before us.

In Conclusion

To learn more about Advanced Wellness and Pain’s innovative treatment options, visit their website here or call them at (480) 546-5615.

Simone Biles Ignites a Movement: How One Voice Sparked a Fire for the Future of the Olympic Torch

How the Public Views Our Olympic Athletes

Most stories stemming from the Olympics share the impossible-sounding feats performed by the best athletes from countries around the world, and the most iconic are ones where said athletes push through pain, tragedy, and mental blockades.

Kerri Strug, a retired American gymnast from Arizona, once part of the 1996 Olympic team dubbed the ‘Magnificent Seven’, won gold for Team USA after completing her vault routine with an injured ankle. Thanks to her, the country won the team competition for the first time ever.

Michael Phelps remains one of the most decorated Olympians ever, and has his sport to thank for making him a household name. He’s earned 23 gold medals, 3 silver, and 2 bronze for a whopping total of 28. He is the face of the sport, and his accomplishments are the drive for many who are striving to be the next Phelps.

What many don’t know is Phelps struggled to find his own identity after retiring from the sport in 2016. In his HBO Sports documentary, “The Weight of Gold,” he says, “Yeah, I won a s–t ton of medals. I had a great career. So what? I thought of myself as just a swimmer. Not a human being.”

Remember Strug? She was a teenager during the ‘96 Olympics, where she injured her ankle on her first vault attempt. It was thought that her next attempt was the difference of gold or silver for Team USA. The weight of the country was on her shoulders, or so she thought.

“Do we need this?” she had asked her coach, desperate to find an alternative that didn’t mean landing hard on her injured foot. She was given no way out and had to be carried off the mat after her second attempt—where she stuck the landing.

It was because of that final vault that won her country gold that she left the Olympic Games a hero, but she was soon forced to retire after struggling to keep up thanks to her injured foot.

Glamour Magazine collaborated with Elite-level gymnasts prior to their participation in the Olympic Prelims of June 2021 for a documentary called, “Defying Gravity: The Untold Story of Women’s Gymnastics” where they reveal that Strug never needed to compete in that final vault. Team USA had already won the gold. Her sacrifice was for naught.

These are the stories that people take away from the Olympics. We cheer for the medal ceremonies and shed tears for the sob stories, but it’s the sacrifices that stick with us, for better or for worse. These sacrifices of self, of health, of mental toughness have been viewed as strength.

Strug and Phelps rocked the boat by speaking out about their mental health post-Olympics, but then Simone Biles appeared, and she’s set on capsizing it.

The Greatest of All Time

Simone Biles is an American gymnast from Texas who got an early start in the sport, beginning when she was around six years old. With a combined total of 32 Olympic and World Championship medals under her belt, Biles is tied with only one other person as the most decorated gymnast of all time. She has four skills named after her, a feat that only occurs if the gymnast performs it at a major international competition, like the Olympics. With her capabilities she is, quite literally, considered to be the greatest athlete of all time.

She was a no-brainer for Team USA, and her scores blew her fellow competitors out of the water at the June Preliminaries. With Biles on the team, America could rest easy knowing no other country had the talent to compete for gold.

Then Tokyo happened, and Biles messed up on vault, which is one of her personal favorites.

Announcers were unable to hide their shock, the crowd emitted worried gasps, and her teammates tried to look away.

She unexpectedly withdrew from the women’s team finals following the vault event, citing mental health concerns as well as fear for her safety should she continue on. Biles admitted that she had lost sense of where she was in the air after launching herself from the vault, which is a major deal in a sport where landing on your feet means everything.

The world watched on, scouring social media while waiting for Biles herself to comment on what had happened. As many speculated that she was embarrassed by her blunder and came to their own conclusions that she was selfish not to continue, many more stepped forward to rally around their Olympic hero.

She eventually did release a statement, tweeting, “the outpouring of love & support I’ve received has made me realize I’m more than my accomplishments and gymnastics which I never truly believed before [white heart emoji].”

Biles returned to the floor days later, after finding refuge in a private Japanese gym to prepare for her Olympic comeback, for the beam event where she earned a bronze medal to add to her repertoire.

What This Means Moving Forward

Hours after being awarded her seventh Olympic medal, Simone Biles said that her biggest takeaway from the 2020 Olympics was to “put your mental health first.” Often this is an epiphany that doesn’t befall athletes until long after they’ve stepped away from the spotlight, their sport, the Games as a whole.

But with Biles still in the running and rumored to be preparing for the 2024 Olympics, with this movement encouraging others to speak up about their own mental health, it’s possible we’ll see less Phelps’ and Strugs’– people who lose themselves in the sport with no resources to fall back on.

We’ll see athletes at their physical best, wowing audiences and inspiring future generations who watch on from their television screens.

We’ll see them with broad smiles as they stand on podiums, cross finish lines, prepare for their dives.

We’ll see less of our heroes crashing and burning, and watch as their names trailblaze the path for those who will come after them.

For more reasons than just what she can do in the air, Biles continues to show she is, in fact, one of the greatest of all time.